Cargando…
Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine
The clinical efficacy of gastroprotective drugs or low-dose H(2) receptor antagonists in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy is limited. The aim of the present study was to investigate efficacy of rebamipide and famotidine in Helicobacter pylori (H. pylo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
the Society for Free Radical Research Japan
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2459250/ https://www.ncbi.nlm.nih.gov/pubmed/18648657 http://dx.doi.org/10.3164/jcbn.2008041 |
_version_ | 1782157419532517376 |
---|---|
author | Naito, Yuji Iinuma, Shoji Yagi, Nobuaki Boku, Yoshio Imamoto, Eiko Takagi, Tomohisa Handa, Osamu Kokura, Satoshi Yoshikawa, Toshikazu |
author_facet | Naito, Yuji Iinuma, Shoji Yagi, Nobuaki Boku, Yoshio Imamoto, Eiko Takagi, Tomohisa Handa, Osamu Kokura, Satoshi Yoshikawa, Toshikazu |
author_sort | Naito, Yuji |
collection | PubMed |
description | The clinical efficacy of gastroprotective drugs or low-dose H(2) receptor antagonists in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy is limited. The aim of the present study was to investigate efficacy of rebamipide and famotidine in Helicobacter pylori (H. pylori)-negative healthy volunteers taking NSAID. This study was a randomized, two way crossover study comparing the preventive effect rebamipide 100 mg, t.i.d. and famotidine 10 mg, b.i.d against indomethacin (25 mg, t.i.d.)-induced gastric mucosal injury in H. pylori-negative healthy volunteers. 12 subjects satisfied criteria and were randomized. Endoscopy was performed at baseline and again after the treatment for 7 days, and symptoms were recorded during the treatment. Tissue levels of lipid peroxides and myeloperoxidase and serum indomethacin concentrations were also measured. Subjective symptoms were developed in 58% (7/12) of the rebamipide group, and in 75% (9/12) of the famotidine group (no significant differences). The incidence of gastric lesions (modified Lanza score 2 or higher) was 17% (2/12) in the rebamipide group and 25% (3/12) in the famotidine group. Peptic ulcers did not occur in both groups. There were no significant differences in tissue levels of lipid peroxide and myeloperoxidase and serum level of indomethacin between two groups after the treatment. In conclusion, these data recommend rebamipide (100 mg, t.i.d.) or famotidine (10 mg, b.i.d.) for the prevention of acute gastric injury induced by NSAID in patients without a particular risk factor. |
format | Text |
id | pubmed-2459250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | the Society for Free Radical Research Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-24592502008-07-22 Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine Naito, Yuji Iinuma, Shoji Yagi, Nobuaki Boku, Yoshio Imamoto, Eiko Takagi, Tomohisa Handa, Osamu Kokura, Satoshi Yoshikawa, Toshikazu J Clin Biochem Nutr Original Article The clinical efficacy of gastroprotective drugs or low-dose H(2) receptor antagonists in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy is limited. The aim of the present study was to investigate efficacy of rebamipide and famotidine in Helicobacter pylori (H. pylori)-negative healthy volunteers taking NSAID. This study was a randomized, two way crossover study comparing the preventive effect rebamipide 100 mg, t.i.d. and famotidine 10 mg, b.i.d against indomethacin (25 mg, t.i.d.)-induced gastric mucosal injury in H. pylori-negative healthy volunteers. 12 subjects satisfied criteria and were randomized. Endoscopy was performed at baseline and again after the treatment for 7 days, and symptoms were recorded during the treatment. Tissue levels of lipid peroxides and myeloperoxidase and serum indomethacin concentrations were also measured. Subjective symptoms were developed in 58% (7/12) of the rebamipide group, and in 75% (9/12) of the famotidine group (no significant differences). The incidence of gastric lesions (modified Lanza score 2 or higher) was 17% (2/12) in the rebamipide group and 25% (3/12) in the famotidine group. Peptic ulcers did not occur in both groups. There were no significant differences in tissue levels of lipid peroxide and myeloperoxidase and serum level of indomethacin between two groups after the treatment. In conclusion, these data recommend rebamipide (100 mg, t.i.d.) or famotidine (10 mg, b.i.d.) for the prevention of acute gastric injury induced by NSAID in patients without a particular risk factor. the Society for Free Radical Research Japan 2008-07 2008-07-01 /pmc/articles/PMC2459250/ /pubmed/18648657 http://dx.doi.org/10.3164/jcbn.2008041 Text en Copyright © 2008 JCBN This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Naito, Yuji Iinuma, Shoji Yagi, Nobuaki Boku, Yoshio Imamoto, Eiko Takagi, Tomohisa Handa, Osamu Kokura, Satoshi Yoshikawa, Toshikazu Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine |
title | Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine |
title_full | Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine |
title_fullStr | Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine |
title_full_unstemmed | Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine |
title_short | Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine |
title_sort | prevention of indomethacin-induced gastric mucosal injury in helicobacter pylori-negative healthy volunteers: a comparison study rebamipide vs famotidine |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2459250/ https://www.ncbi.nlm.nih.gov/pubmed/18648657 http://dx.doi.org/10.3164/jcbn.2008041 |
work_keys_str_mv | AT naitoyuji preventionofindomethacininducedgastricmucosalinjuryinhelicobacterpylorinegativehealthyvolunteersacomparisonstudyrebamipidevsfamotidine AT iinumashoji preventionofindomethacininducedgastricmucosalinjuryinhelicobacterpylorinegativehealthyvolunteersacomparisonstudyrebamipidevsfamotidine AT yaginobuaki preventionofindomethacininducedgastricmucosalinjuryinhelicobacterpylorinegativehealthyvolunteersacomparisonstudyrebamipidevsfamotidine AT bokuyoshio preventionofindomethacininducedgastricmucosalinjuryinhelicobacterpylorinegativehealthyvolunteersacomparisonstudyrebamipidevsfamotidine AT imamotoeiko preventionofindomethacininducedgastricmucosalinjuryinhelicobacterpylorinegativehealthyvolunteersacomparisonstudyrebamipidevsfamotidine AT takagitomohisa preventionofindomethacininducedgastricmucosalinjuryinhelicobacterpylorinegativehealthyvolunteersacomparisonstudyrebamipidevsfamotidine AT handaosamu preventionofindomethacininducedgastricmucosalinjuryinhelicobacterpylorinegativehealthyvolunteersacomparisonstudyrebamipidevsfamotidine AT kokurasatoshi preventionofindomethacininducedgastricmucosalinjuryinhelicobacterpylorinegativehealthyvolunteersacomparisonstudyrebamipidevsfamotidine AT yoshikawatoshikazu preventionofindomethacininducedgastricmucosalinjuryinhelicobacterpylorinegativehealthyvolunteersacomparisonstudyrebamipidevsfamotidine |